Gemphire Therapeutics – $30 Million IPO

San Diego – August 22, 2016 – Cooley advised the underwriters on Gemphire Therapeutics Inc.'s $30 million initial public offering. The company's common stock now trades on The NASDAQ Global Market under the symbol "GEMP."

Jefferies and RBC Capital Markets acted as joint book-running managers for the offering. Canaccord Genuity acted as co-lead manager and Laidlaw & Company (UK) Ltd. and LifeSci Capital acted as co-managers.

Gemphire is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease, and nonalcoholic fatty liver disease.

The Cooley corporate and securities team advising the underwriters included Div Gupta, Charlie Kim, Nicole Brookshire, Siana Lowrey, Kristin VanderPas, Jonie Kondracki, Susan Walker and Adrienne Directo.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.

Related Contacts
Div Gupta Partner New York
Charlie Kim Partner San Diego, Los Angeles
Nicole Brookshire Partner Boston
Natasha Leskovsek Of Counsel Washington, DC
Kevin King Partner Washington, DC
Bill Christiansen Partner Seattle
Susan Cooper Philpot Retired Partner San Francisco
Phil Mitchell Partner New York
Siana Lowrey Partner San Francisco
Kristin VanderPas Partner San Francisco
Jonie Kondracki Partner San Francisco
Karen Tsai Special Counsel Washington, DC